ライフサイエンスコーパス: CRPV

1 CRPV capsids were observed in closed (compact) and open

2 CRPV infection of outbred rabbits serves as a model for

3 CRPV-E8 is a small open reading frame, coding for a 50-a

4 At both 6 and 12 months after CRPV L1 VLP immunizations, strong protection was also ob

5 ll possible pairings to rabbits 1 week after CRPV infection.

6 At 2 weeks after CRPV L1 VLP immunizations, the rabbits were completely p

7 trong to partial protective immunity against CRPV infection.

8 ) E6 gene induced partial protection against CRPV challenge and that the vaccine's effects were great

9 that induces significant protection against CRPV challenge was used in a superior vaccination regime

10 (E1-rLm) to protect outbred rabbits against CRPV- and CRPV DNA-induced tumors.

11 to protect outbred rabbits against CRPV- and CRPV DNA-induced tumors.

12 of drugs which are inhibitory to the HPV and CRPV replication and gene expression.

13 abbits were then infected with both ROPV and CRPV and monitored for the development of oral and cutan

14 1-rLm immunization generated a systemic anti-CRPV E1 cell-mediated immune response which protected ou

15 Furthermore, VSV-based CRPV vaccination cured all of the papillomas in 5 of 30

16 n, we showed that the complex formed between CRPV E2 and the cognate binding site was less stable tha

17 persistence of abortive infections caused by CRPV offers advantages for the development of therapeuti

18 Furthermore, papillomas induced by CRPV genomic DNA deficient for L2 expression grew at the

19 ected outbred rabbits from tumors induced by CRPV or CRPV DNA challenge.

20 ced complete regression of tumors induced by CRPV.

21 ntigenic competition between the coexpressed CRPV proteins.

22 tely absent in rabbits immunized with either CRPV peptide.

23 administration of four DNA plasmids encoding CRPV E1, E2, E6, and E7 genes, respectively.

24 tested the efficacy of protection following CRPV challenge.

25 Rabbits were completely protected from CRPV-induced papillomas after VSV-L1 vaccination and boo

26 s of CRPV effectively protected rabbits from CRPV challenge but not from papillomas induced by cutane

27 1 VLPs were challenged with both homologous (CRPV capsid) and chimeric (HPV-16 capsid) particles.

28 CRPV) was tested for therapeutic efficacy in CRPV-infected rabbits.

29 Infectious CRPV and human papillomavirus type 11 L1 VLPs were used

30 with 10-fold serial dilutions of infectious CRPV at 2 weeks, 6 months, and 12 months after immunizat

31 cond strategy was to vaccinate with multiple CRPV early genes to increase the breadth of the CRPV-spe

32 No CRPV DNA was detected either in the regression sites or

33 Challenge of CRPV peptide-immune rabbits with the viral genome result

34 ing that the vaccination led to clearance of CRPV from all infected sites.

35 CSF priming greatly augmented the effects of CRPV E6 vaccination.

36 gies for augmenting the clinical efficacy of CRPV E6 vaccination were evaluated.

37 An rVSV expressing L1 of CRPV (VSV-L1) was characterized for the protective abili

38 We generated a panel of CRPV genomes that contained chimeric and mutant progress

39 on with either N-terminal L2 polypeptides of CRPV effectively protected rabbits from CRPV challenge b

40 someres, as do BPV-1 and HPV-1, but the open CRPV capsids are approximately 2 nm larger in radius.

41 tbred rabbits from tumors induced by CRPV or CRPV DNA challenge.

42 in (L1) of cottontail rabbit papillomavirus (CRPV) and tested the efficacy of protection following CR

43 ound after cottontail rabbit papillomavirus (CRPV) challenge when compared with results in normal rab

44 lated with cottontail rabbit papillomavirus (CRPV) DNA.

45 study the cottontail rabbit papillomavirus (CRPV) E2 protein as a transcriptional regulator because

46 A cottontail rabbit papillomavirus (CRPV) E6 DNA vaccine that induces significant protection

47 n with the cottontail rabbit papillomavirus (CRPV) E6 gene induced partial protection against CRPV ch

48 HPV capsid/cottontail rabbit papillomavirus (CRPV) genome particles to permit the direct testing of H

49 Cottontail rabbit papillomavirus (CRPV) is a highly oncogenic papillomavirus and has been

50 In a cottontail rabbit papillomavirus (CRPV) model, immunization with plasmid DNA encoding L1 e

51 ave used a cottontail rabbit papillomavirus (CRPV) rabbit model to test the ability of recombinant L.

52 strains of cottontail rabbit papillomavirus (CRPV) that differ by approximately 5% in base pair seque

53 (VLPs) of cottontail rabbit papillomavirus (CRPV) to determine whether these antigens could induce l

54 Cottontail rabbit papillomavirus (CRPV) was reported previously to be a T = 7laevo (left-h

55 protein of cottontail rabbit papillomavirus (CRPV) was tested for therapeutic efficacy in CRPV-infect

56 (BPV1), or cottontail rabbit papillomavirus (CRPV) were produced in bacteria.

57 us (ROPV), cottontail rabbit papillomavirus (CRPV), bovine papillomavirus type 1, and human papilloma

58 The cottontail rabbit papillomavirus (CRPV)-rabbit model has been used in several studies for

59 ity in the cottontail rabbit papillomavirus (CRPV)-rabbit model of high-risk HPV infection.

60 ction with cottontail rabbit papillomavirus (CRPV).

61 e of the equivalent region of the persistent CRPV strain E6, played a dominant role in the conversion

62 ant role in the conversion of the persistent CRPV strain to one showing high rates of spontaneous reg

63 he rabbit oral (ROPV) and cottontail rabbit (CRPV) papillomaviruses were used to immunize rabbits.

64 rminal 77-amino-acid region of the regressor CRPV strain E6, which contained 15 amino acid residues t

65 a model for oncogenic papillomaviruses since CRPV-induced papillomas progress with high frequency to

66 In this study, we found that CRPV E8 immunization eliminated virus-induced papillomas

67 Furthermore, we showed that CRPV E2 binding to its transcriptional regulatory sequen

68 s may spontaneously regress, suggesting that CRPV can also serve as a model to develop therapeutic va

69 The CRPV structure determined by cryoelectron microscopy and

70 Because the CRPV genome can accommodate significant modifications, t

71 study, three new VSV vectors expressing the CRPV E1, E2, or E7 protein were produced and compared to

72 n accommodate significant modifications, the CRPV/HLA-A2.1 rabbit model has the potential to be used

73 e containing ubiquitin-fused versions of the CRPV E1, E2, and E7 genes was tested.

74 acid change (G252E) in the E6 protein of the CRPV progressor strain led to high frequencies of sponta

75 V early genes to increase the breadth of the CRPV-specific response.

76 Earlier observations had shown that the CRPV nonstructural genes E1, E2, and E6 induced strong t

77 first was to fuse a ubiquitin monomer to the CRPV E6 protein to enhance antigen processing and presen

78 mino-acid protein, that is colinear with the CRPV E6 gene and has features similar to those of the bo

79 nted by simultaneous vaccination against two CRPV proteins, the four vaccines were delivered individu

80 DNA vaccines encoding the wild-type CRPV E1-E2, E6, or E7 protein were tested alone and in a

81 the same rate as those induced by wild-type CRPV genomic DNA, further suggesting that the L2 polypep

82 against cutaneous and mucosal challenge with CRPV and ROPV, respectively, papillomaviruses that are e

83 pillomas induced by cutaneous challenge with CRPV genomic DNA.

84 inst papilloma formation upon challenge with CRPV.

85 otection against experimental challenge with CRPV.

86 olypeptides and concurrently challenged with CRPV and rabbit oral papillomavirus (ROPV).

87 immunizations, rabbits were challenged with CRPV at low, moderate, and high stringencies and monitor

88 cytogenes or E1-rLm and then challenged with CRPV or viral DNA.

89 tion in rabbits subsequently challenged with CRPV.

90 were then inoculated at 350-400 p.s.i. with CRPV DNA.

91 Animals vaccinated with CRPV, HPV type 16 (HPV-16), or HPV-11 VLPs were challeng